Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This team has identified a subset of childhood Acute Lymphoblastic Leukemia (ALL) with specific genetic abnormalities in the leukemia cells (Ph-like ALL) that has poor survival. Some Ph-like ALL patients have genetic abnormalities that make their leukemia cells sensitive to a targeted therapy (dasatinib), which has many fewer side effects than chemotherapy. This consortium is using a COG clinical trial to help identify which children should respond to dasatinib, and then will add this targeted therapy to their chemotherapy to try to improve survival. Awarded at the University of Colorado and transferred to the Children's Hospital of Philadelphia. Funds administered by the Children's Hospital of Philadelphia.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's:COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

Neuroblastoma is one of the most common solid tumors of childhood, and patients have very low survival if it recurs after initial treatment. Natural killer (NK) cells are white blood cells that are part of your body's natural defense against cancer, and these cells are particularly good at killing neuroblastoma when they work together with immune stimulators and anti-cancer antibodies. This team has developed a new way to grow large numbers of very active NK cells. The project is testing whether NK cells in combination with the anti-neuroblastoma antibody, ch14.18, and the immune activator, lenalidomide, will improve survival for children with neuroblastoma. Awarded at University of Texas M.D. Anderson Cancer Center and transferred to The Research Institute at Nationwide Children's. Funds administered by The Research Institute at Nationwide Children's Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Multimodal immunotherapy for neuroblastoma Consortium. For a description of this project, see the consortium grant made to the lead institution: The Research Institute at Nationwide Children's Hospital, Columbus, OH.